JP2011521654A - Ｒｎａに基づくウイルスベクター系を提供するペスチウイルスレプリコン - Google Patents

Ｒｎａに基づくウイルスベクター系を提供するペスチウイルスレプリコン Download PDF

Info

Publication number
JP2011521654A
JP2011521654A JP2011512010A JP2011512010A JP2011521654A JP 2011521654 A JP2011521654 A JP 2011521654A JP 2011512010 A JP2011512010 A JP 2011512010A JP 2011512010 A JP2011512010 A JP 2011512010A JP 2011521654 A JP2011521654 A JP 2011521654A
Authority
JP
Japan
Prior art keywords
replicon
gene
pro
protein
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011512010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521654A5 (enExample
Inventor
ヨン ドゥリ トラッティン
ニコラス ルグリ
ケネス チャールズ マッカルー
Original Assignee
インスティトゥート フュア ヴィルスクランクハイテン ウント イムンプロフィラクセ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスティトゥート フュア ヴィルスクランクハイテン ウント イムンプロフィラクセ filed Critical インスティトゥート フュア ヴィルスクランクハイテン ウント イムンプロフィラクセ
Publication of JP2011521654A publication Critical patent/JP2011521654A/ja
Publication of JP2011521654A5 publication Critical patent/JP2011521654A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24341—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24342—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24341—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011512010A 2008-06-04 2009-05-30 Ｒｎａに基づくウイルスベクター系を提供するペスチウイルスレプリコン Pending JP2011521654A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08010222.1 2008-06-04
EP08010222A EP2130912A1 (en) 2008-06-04 2008-06-04 Pestivirus replicons providing an RNA-based viral vector system
PCT/EP2009/003892 WO2009146867A1 (en) 2008-06-04 2009-05-30 Pestivirus replicons providing an rna-based viral vector system

Publications (2)

Publication Number Publication Date
JP2011521654A true JP2011521654A (ja) 2011-07-28
JP2011521654A5 JP2011521654A5 (enExample) 2015-08-27

Family

ID=39967852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512010A Pending JP2011521654A (ja) 2008-06-04 2009-05-30 Ｒｎａに基づくウイルスベクター系を提供するペスチウイルスレプリコン

Country Status (5)

Country Link
US (2) US9249395B2 (enExample)
EP (2) EP2130912A1 (enExample)
JP (1) JP2011521654A (enExample)
CA (1) CA2723999C (enExample)
WO (1) WO2009146867A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2130912A1 (en) * 2008-06-04 2009-12-09 Institut für Viruskrankeiten und Immunprophylaxe Pestivirus replicons providing an RNA-based viral vector system
EP2590676B1 (en) 2010-07-06 2016-08-17 GlaxoSmithKline Biologicals SA Virion-like delivery particles for self-replicating rna molecules
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
SI3243526T1 (sl) 2010-07-06 2020-02-28 Glaxosmithkline Biologicals S.A. Dostava RNA za sprožitev večih imunskih poti
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
RS63329B1 (sr) 2010-08-31 2022-07-29 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
AU2011295938B2 (en) * 2010-08-31 2016-01-14 Glaxosmithkline Biologicals S.A. Lipids suitable for liposomal delivery of protein-coding RNA
CN103269713B (zh) 2010-10-11 2016-01-20 诺华有限公司 抗原递送平台
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
JP2014520806A (ja) * 2011-07-06 2014-08-25 ノバルティス アーゲー Ｒｎａ分子の送達のための有用なｎ：ｐ比を有するリポソーム
AU2017207744A1 (en) 2016-01-11 2018-07-26 Verndari, Inc. Microneedle compositions and methods of using same
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
JP7364334B2 (ja) 2016-06-24 2023-10-18 ロンザ リミテッド 直径可変型バイオリアクタ
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
CA3049244A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
IL294290A (en) 2019-12-31 2022-08-01 Elixirgen Therapeutics Inc Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
US11976019B2 (en) 2020-07-16 2024-05-07 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
KR20240123832A (ko) 2021-12-16 2024-08-14 아퀴타스 테라퓨틱스 인크. 지질 나노입자 제형에 사용하기 위한 지질
EP4474015A1 (en) 2023-06-05 2024-12-11 Veterna Srl Noda-like rna-vaccine pharmacon and production and uses thereof
CN118955658A (zh) * 2024-07-26 2024-11-15 华南农业大学 一种重组猪瘟病毒Npro蛋白、抗猪瘟病毒Npro蛋白的多克隆抗体及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053766A1 (en) * 1999-03-08 2000-09-14 Stichting Dienst Landbouwkundig Onderzoek Non-spreading pestivirus
WO2004092386A2 (en) * 2003-04-11 2004-10-28 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Inducing a t cell response with recombinant pestivirus replicons or recombinant pestivirus replicon-transfected dendritic cells
JP2005508610A (ja) * 2001-05-23 2005-04-07 インスティティ・パスツール 異種タンパク質の製造に有用なプラス鎖ｒｎａウイルスゲノムに由来するレプリコン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168942B1 (en) * 1998-11-10 2001-01-02 Pfizer Inc. Attenuated forms of bovine viral diarrhea virus
US7244434B2 (en) * 2002-08-13 2007-07-17 Intervet International B.V. Replicons of pestviruses that do not express C and or E1 protein and infectious viral particles containing same, that can be used in vaccines
EP2366719B1 (en) * 2005-04-26 2018-02-21 Sandoz AG Process of production of a recombinant polypeptide by fusion with an autoprotease
US20080305130A1 (en) * 2005-12-07 2008-12-11 Chichi Huang Marked Bovine Viral Diarrhea Virus Vaccines
EP2130912A1 (en) * 2008-06-04 2009-12-09 Institut für Viruskrankeiten und Immunprophylaxe Pestivirus replicons providing an RNA-based viral vector system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053766A1 (en) * 1999-03-08 2000-09-14 Stichting Dienst Landbouwkundig Onderzoek Non-spreading pestivirus
JP2005508610A (ja) * 2001-05-23 2005-04-07 インスティティ・パスツール 異種タンパク質の製造に有用なプラス鎖ｒｎａウイルスゲノムに由来するレプリコン
WO2004092386A2 (en) * 2003-04-11 2004-10-28 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Inducing a t cell response with recombinant pestivirus replicons or recombinant pestivirus replicon-transfected dendritic cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JPN6014000534; Ｊｏｕｒｎａｌ　ｏｆ　Ｖｉｒｏｌｏｇｙ Ｖｏｌ．７２, 1998, ｐ．７６８１-７６８４ *
JPN6014000535; Ｊｏｕｒｎａｌ　ｏｆ　Ｖｉｒｏｌｏｇｙ Ｖｏｌ．７２, 1998, ｐ．５３１８-５３２２ *
JPN6014000537; Ｖｅｔ．Ｒｅｓ． Ｖｏｌ．３７, 2006, ｐ．６５５-６７０ *
JPN6014052780; Ｅｕｒ．　Ｊ．　Ｉｍｍｕｎｏｌ．，１９９３年，Ｖｏｌ．２３，ｐ．１７１９-１７２２ *
JPN6014052783; 日本獣医学会学術集会講演要旨集，２００５年，Ｖｏｌ．１４０，ｐ．１１２，ＤＶ-５５ *
JPN6014052786; Ｊｏｕｒｎａｌ　ｏｆ　Ｖｉｒｏｌｏｇｉｃａｌ　Ｍｅｔｈｏｄｓ，１９９８年，Ｖｏｌ．７０，ｐ．９３-１０１ *
JPN6014052787; 日本獣医学会学術集会講演要旨集，２００６年，Ｖｏｌ．１４２，ｐ．８６，ＤＶ-２９ *
JPN6014052789; Ｊｏｕｒｎａｌ　ｏｆ　Ｖｉｒｏｌｏｇｙ，２００４年，Ｖｏｌ．７８，ｐ．２４１４-２４２５ *
JPN6014052791; 日本ウイルス学会第５４回学術集会プログラム・抄録集，２００６年，ｐ．１５７，１Ｂ０１ *

Also Published As

Publication number Publication date
EP2130912A1 (en) 2009-12-09
US9249395B2 (en) 2016-02-02
CA2723999A1 (en) 2009-12-10
US20160108372A1 (en) 2016-04-21
CA2723999C (en) 2022-03-15
WO2009146867A1 (en) 2009-12-10
US9670466B2 (en) 2017-06-06
EP2297309A1 (en) 2011-03-23
US20110189224A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
US9670466B2 (en) Pestivirus replicons providing an RNA-based viral vector system
JP5538729B2 (ja) 偽感染性フラビウイルスおよびそれらの使用
EP0977587B1 (en) Chimeric flavivirus vaccines
US8784839B2 (en) Attenuated live vaccines
KR101158741B1 (ko) ＨＣＶ의 폴리프로테인 ＮＳ3/ＮＳ4 및 폴리펩티드ＮＳ5ｂ를 포함하는 조성물, 이에 상응하는 뉴클레익서열을 함유하는 발현 벡터, 및 그의 치료적 용도
EP2303320B1 (en) Attenuated pestivirus
US20190111125A1 (en) Bacterial artificial chromosomes
KR100939050B1 (ko) Ｂｖｄｖ 바이러스-유사 입자
Suter et al. Immunogenic and replicative properties of classical swine fever virus replicon particles modified to induce IFN-α/β and carry foreign genes
CA2663142C (en) Pestivirus mutant for use in a vaccine
AU2005279303B2 (en) Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
EP3498850B1 (en) Heterologous expression cassette, dna construct and vaccine composition for immunizing against flavivirus and/or other pathogens
AU3757199A (en) Chimeras of hepatitis c virus and bovine viral diarrhea virus
US20170128563A1 (en) Live Attenuated Classical Swine Fever Vaccine Based in Genetic Manipulation of a Putative Fusion Peptide Area in the Virus Structural Glycoprotein E2
EP1650308A1 (en) Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
Arch Heinz et al.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150609

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150901